Stock AKLI AKILI, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Akili, Inc. Stock

Equities

AKLI

US00974B1070

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
0.41 USD -2.38% Intraday chart for Akili, Inc. -3.67% -15.83%
May. 14 Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M MT
Apr. 30 Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product CI

Financials (USD)

Sales 2024 * 7.64M Sales 2025 * 11.67M Capitalization 32.93M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -4.38 x
Net cash position 2024 * 66.4M Net cash position 2025 * 87.99M EV / Sales 2025 * -4.72 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.48%
More Fundamentals * Assessed data

Chart Akili, Inc.

Dynamic Chart

Latest news about Akili, Inc.

Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M MT
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product CI
Akili, Inc. to Reduce Workforce CI
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd CI
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan DJ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan CI
Akili Appoints John Spinale to the Board and Audit Committee CI
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024 CI
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024 CI
Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board CI
More news

Latest transcript on Akili, Inc.

Logo Akili, Inc.
Akili, Inc., Q3 2023 Earnings Call, Nov 09, 2023
More transcripts

Analyst Recommendations on Akili, Inc.

Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating MT
Morgan Stanley Initiates Akili at Equalweight, $2 Price Target, Cites Uncertainties Regarding EndeavorRx's Launch MT
Morgan Stanley Initiates Akili at Equalweight With $2 Price Target MT
BofA Securities Starts Akili at Neutral With $2 Price Target MT
Credit Suisse Starts Akili at Outperform With $5 Price Target MT
More recommendations

Press releases Akili, Inc.

Akili Reports First Quarter 2024 Financial Results and Provides Business Update BU
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results BU
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update BU
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan AQ
More press releases

Quotes and Performance

1 day-2.38%
1 week-3.67%
Current month+2.50%
1 month+65.32%
3 months+85.02%
6 months-18.00%
Current year-15.83%
More quotes

Highs and lows

1 week
0.40
Extreme 0.4011
0.44
1 month
0.22
Extreme 0.2202
0.49
Current year
0.19
Extreme 0.1912
0.74
1 year
0.19
Extreme 0.1912
1.67
3 years
0.19
Extreme 0.1912
37.58
5 years
0.19
Extreme 0.1912
37.58
10 years
0.19
Extreme 0.1912
37.58
More quotes

Managers and Directors - Akili, Inc.

Managers TitleAgeSince
Matthew Franklin CEO
 Chief Executive Officer 50 22-07-31
W. Martucci FOU
 Founder 42 20-11-30
Scott H. Kollins CTO
 Chief Tech/Sci/R&D Officer - 22-11-30
Members of the board TitleAgeSince
William Jones BRD
 Director/Board Member 60 22-07-31
Mary Hentges BRD
 Director/Board Member 65 22-10-24
John Spinale BRD
 Director/Board Member 54 Feb. 15
More insiders

Quotes

Date Price Change Volume
24-05-24 0.419 +2.20% 65,048
24-05-23 0.41 -2.38% 96,821
24-05-22 0.42 +2.39% 175,281
24-05-21 0.4102 -2.36% 120,193
24-05-20 0.4201 -1.29% 244,476

End-of-day quote Nasdaq, May 22, 2024

More quotes

Company Profile

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.
Sector
Advanced Medical Equipment & Technology
Calendar
2024-08-07 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Akili, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.419 USD
Average target price
0.65 USD
Spread / Average Target
+55.13%
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
AKILI, INC. Stock Akili, Inc.
-15.83% 32.93M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+10.03% 223B
DANAHER CORPORATION Stock Danaher Corporation
+13.59% 195B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+20.01% 144B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+30.83% 111B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.05% 65.01B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+15.38% 53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+3.96% 50.45B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+8.37% 44.15B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+3.27% 36.45B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. AKLI Stock